Close

Top Stories

Boehringer Ingelheim, the world’s second largest animal health company, has been boosting its investment in China by expanding the Asian Veterinary Research & Development (R&D) Center to enhance its research and innovation capacity.

Mitsubishi Tanabe Pharma Corporation MTPC announced that Canagliflozin received the Technology Award Grand Prize at the 50th JCIA Awards.

CPhI & P-MEC China (#CPhIChina) – organized by UBM and UBM SINEXPO – takes place at the Shanghai New International Expo Center (SNIEC) on 20-22nd June 2018.

GlaxoSmithKline plc (GSK) will present extensive data from across its respiratory portfolio, pipeline and early phase research programmes at the American Thoracic Society (ATS) conference in San Diego, USA, 19-23 May 2018.

TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced the latest keynote speakers for its upcoming FutureLink Munich conference to be held June 5-7, 2018.

Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, announced the launch of a new online customer portal designed to enable customers to better monitor project progress and track communications.

Family-owned pharmaceutical company Boehringer Ingelheim presented its latest pipeline updates at a Research & Development press conference entitled ‘Transcending Disease Boundaries’, at its global headquarters in Ingelheim, Germany.

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, and global biotechnology leader CSL Limited announced an exclusive licensing agreement for the development, manufacture and commercialization of recombinant C1 Esterase Inhibitor (C1-INH) proteins for Hereditary Angioedema (HAE) and other potential indications using CEVEC's proprietary CAP(R)Go technology.

On the occasion of its 20th anniversary, the Swiss Biotech Association launches Swiss Biotech Success Stories in recognition of the industry’s many accomplishments.

Biogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 investigational treatment for early Alzheimer’s disease.

Bracket, a leading clinical trial technology and specialty services provider, has won the Best Patient-Focused Technological Development award at the Clinical and Research Excellence (CARE) Awards.

STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec (WuXi STA), announces that it has signed an investment agreement with the government of Shanghai, Jinshan District to build a new R&D center.

Vetter, a global leader in prefilled drug-delivery systems was paid a special visits at its Ravensburg, Germany facilities by Illinois Governor, Bruce Rauner.

CRF Health, the leading provider of patient-centered eSource for the life sciences industry, announced that its TrialMax Touch® and TrialMax Slate® solutions have been selected by a Global Category Japanese Pharmaceutical company for a significant pain trial.

Drug Safety 2018 aims to discuss the latest findings and current thinking on pharmacovigilance. Importantly, it will address the newest regulatory updates and interpretations of them, including the impact of the vital and much awaited Clinical Trial Regulations.

SMi are delighted to have our Chairman, Speaker and Workshop Host, Justin Mason-Home, Director, HPAPI Project Services Limited, onto the speaker panel for HPAPI 2018!

AstraZeneca presented new post-progression outcomes data from an exploratory analysis of the global Phase III FLAURA trial, which assessed the efficacy and safety of Tagrisso (osimertinib) as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

Novartis announced a new post hoc analysis of the pivotal Phase III heart failure study, PARADIGM-HF, demonstrating that treatment with Entresto® (sacubitril/valsartan) helped to preserve kidney function, as assessed by estimated glomerular filtration rate (eGFR), in patients with heart failure with reduced ejection fraction (HFrEF).1

Hercules Pharmaceuticals, a Dutch biopharmaceutical company developing innovative anti-cancer drugs will present a poster, Poster LB-128, at the AACR meeting in Chicago on Monday April 16, 2018, from 8:00am-12:00pm, Poster section 45.

Powder containment and aseptic transfer valve specialist ChargePoint Technology, has appointed two new area managers to support the increased demand for its containment technologies and solutions throughout the US.

CPhI South East Asia organised by UBM has announced that from 2019 onwards it will alternate its annual location between the region’s two largest pharma economies, Indonesia and Thailand.

TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced the latest industry speakers confirmed for FutureLink Munich, which will occur June 6-7, 2018 at the Sheraton Munich Arabellapark Hotel.

Boehringer Ingelheim announced data from the landmark 52-week DYNAGITO® trial which show that in people with COPD (chronic obstructive pulmonary disease), Spiolto®Respimat® (tiotropium/olodaterol 5/5µg) lowers the rate of moderate-to-severe exacerbations compared with Spiriva® Respimat® (tiotropium).

Aptar Pharma, a leading drug delivery systems provider, is proud to announce its leading role in the organization of the forthcoming 7th Innovative Drug Delivery Solutions Symposium (IDDS). The biennial conference is to be held this year at the SORL Hotel Hangzhou, Hangzhou, Chinafrom March 28-30, 2018.

Aptar Pharma, a leading global solution provider of innovative drug delivery systems, is pleased to be a Platinum Sponsor at RDD 2018, taking place from April 22 to April 26 at the JW Marriott Starr Pass Resort and Spa,Tucson, Arizona.

Vetter has won the 2018 ISPE Facility of the Year Award (FOYA) in the Facility of the Future category for its Center for Visual Inspection and Logistics.

Orchard Therapeutics, a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, announced two key additions to its executive leadership team, appointing Jason Meyenburg as chief commercial officer and John Ilett as general counsel & company secretary.

New data from one of the largest prospective ongoing global studies examining the use of oral antithrombotics for stroke prevention in atrial fibrillation (AF) in clinical practice, GLORIATM-AF, were presented at the EHRA 2018, the annual congress of the European Heart Rhythm Association (EHRA).1,2 The registry examined two-year safety and effectiveness outcomes of nearly 5,000 AF patients treated with dabigatran (marketed as Pradaxa®). Results of the completed Phase II of GLORIATM-AF,1 presented during the ‘Late-breaking science – Registries’ session, showed low rates of major bleeding (0.97%) and stroke (0.65%). These findings confirm the sustained safety and effectiveness of dabigatran and are highly consistent with the long-term safety profile observed in other real-world evidence, as well as in randomised clinical trials.

“Long-term, ‘real-world’ data are important to cardiologists as they help build a bigger picture of how an antithrombotic medication works in daily clinical practice,” commented Gregory Y H Lip, MD, Co-Chair of the GLORIATM-AF Steering Committee. “The results from the second phase of GLORIATM-AF underline the safety and effectiveness of dabigatran, which is reassuring for physicians treating patients with atrial fibrillation.”

In an additional analysis from GLORIATM-AF2 the safety of uninterrupted dabigatran for patients undergoing cardiovascular (CV) interventions was evaluated. The rates of major bleeding and stroke/ systemic embolism were very low, i.e. one major bleed and one systemic embolic event occurred in 412 CV interventions that were performed with uninterrupted dabigatran.

“From the first clinical trials such as RE-LY® and RELY-ABLE®, through to numerous real-world studies, both supported by and independent from Boehringer Ingelheim, we get an absolute, consistent picture of the favorable safety of dabigatran,” commented Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “Recent clinical trials in specific settings like RE-CIRCUITTM,3 with dabigatran in AF patients undergoing cardio ablation, again demonstrated the superior safety of Pradaxa® compared to standard-of-care. The prospective, long-term data for dabigatran from GLORIATM-AF now add one further piece to complete this picture with profound real-world evidence.”

AF is the most common cardiac rhythm disorder worldwide, with numbers expected to rise in the coming years.4 Overall, people diagnosed with AF have a five-fold increased risk of stroke,5 which occurs when a blood clot blocks a vessel in the brain. Each year three million patients suffer AF-related strokes.6,7New data from one of the largest prospective ongoing global studies examining the use of oral antithrombotics for stroke prevention in atrial fibrillation (AF) in clinical practice, GLORIATM-AF, were presented at the EHRA 2018, the annual congress of the European Heart Rhythm Association (EHRA).1,2 The registry examined two-year safety and effectiveness outcomes of nearly 5,000 AF patients treated with dabigatran (marketed as Pradaxa®). Results of the completed Phase II of GLORIATM-AF,1 presented during the ‘Late-breaking science – Registries’ session, showed low rates of major bleeding (0.97%) and stroke (0.65%). These findings confirm the sustained safety and effectiveness of dabigatran and are highly consistent with the long-term safety profile observed in other real-world evidence, as well as in randomised clinical trials.

“Long-term, ‘real-world’ data are important to cardiologists as they help build a bigger picture of how an antithrombotic medication works in daily clinical practice,” commented Gregory Y H Lip, MD, Co-Chair of the GLORIATM-AF Steering Committee. “The results from the second phase of GLORIATM-AF underline the safety and effectiveness of dabigatran, which is reassuring for physicians treating patients with atrial fibrillation.”

In an additional analysis from GLORIATM-AF2 the safety of uninterrupted dabigatran for patients undergoing cardiovascular (CV) interventions was evaluated. The rates of major bleeding and stroke/ systemic embolism were very low, i.e. one major bleed and one systemic embolic event occurred in 412 CV interventions that were performed with uninterrupted dabigatran.

“From the first clinical trials such as RE-LY® and RELY-ABLE®, through to numerous real-world studies, both supported by and independent from Boehringer Ingelheim, we get an absolute, consistent picture of the favorable safety of dabigatran,” commented Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “Recent clinical trials in specific settings like RE-CIRCUITTM,3 with dabigatran in AF patients undergoing cardio ablation, again demonstrated the superior safety of Pradaxa® compared to standard-of-care. The prospective, long-term data for dabigatran from GLORIATM-AF now add one further piece to complete this picture with profound real-world evidence.”

AF is the most common cardiac rhythm disorder worldwide, with numbers expected to rise in the coming years.4 Overall, people diagnosed with AF have a five-fold increased risk of stroke,5 which occurs when a blood clot blocks a vessel in the brain. Each year three million patients suffer AF-related strokes.

SMi are delighted to present the 2nd annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) conference being held at Holiday Inn, Kensington Forum, London, on the 21st – 22nd May 2018.

The Pistoia Alliance, a global, not for profit alliance that works to lower barriers to innovation in life sciences R&D, is calling upon the industry to support the ‘Lab of the Future’ (LoTF) through greater collaboration.

Increased international generic API companies and suppliers are reported at next month’s CPhI Japan 2018, traditionally an innovative drug focussed market, due to recent changes in the country.

Clinerion’s Board of Directors announces the appointment of Ian Rentsch as new CEO of the company, effective April 1, 2018.

Gilead Sciences, Inc. announced that Norbert Bischofberger, PhD, has decided to step down from his role as Executive Vice President, Research and Development and Chief Scientific Officer, effective at the end of April 2018.

Novartis announced changes to its senior leadership team to support the implementation of its strategic priorities. Bertrand Bodson, Chief Digital Officer, Steffen Lang, Global Head Novartis Technical Operations, and Shannon Klinger, Chief Ethics, Risk and Compliance Officer, have been appointed to the Executive Committee of Novartis (ECN).

Recipharm, the contract development and manufacturing organisation (CDMO), announces its new Blow-fill-seal machinery is now operational following a substantial investment last year at its facility in Kaysersberg, France.

An expert judging panel of IndustryWeek editors and advisors has selected the Thermo Fisher Scientific Auburn manufacturing site in Alabama as one of seven 2017 Best Plant winners.

Recipharm has announced that its 2017 International Environmental Award will be presented to Karen Kidd, Professor in Biology, and Geography & Earth Sciences at McMaster University in Hamilton, Ontario and Jarislowsky Chair in Environment and Health.

Powder containment and aseptic transfer valve specialist ChargePoint Technology has obtained the highest level of quality accreditation at its Liverpool, UK facility, to enable future product development for use in hazardous environments.

The pharma major will distribute Tocilizumab and Syndyma -- the second brand of Roche's cancer therapy bevacizumab -- in India.

The Regulatory Affairs Professionals Society (RAPS) continues its support of medical device professionals in Europe with the launch of a workshop focused on 510(k) premarket submissions to the US Food and Drug Administration (FDA).

A small specialist British engineering company called Priorclave celebrates 30 years in the design, manufacture and world-wide supply of an extensive range of laboratory and research grade autoclaves.

Lonza has announced a panel of top endotoxin experts to present at the 4th Global Endotoxin Testing Summit from 12-14 June 2018, in Annapolis, MD (USA).

Haverford Trust Co. lifted its position in shares of Eli Lilly and Co by 16.3% during the fourth quarter, according to the company in its most recent filing with the SEC.

Bristol-Myers Squibb Company announced that its Board of Directors has elected José Baselga, M.D., Ph.D., to the Board, effective March 1, 2018. Dr. Baselga will serve as a member of Science & Technology Committee of the Board of Directors.

Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the Group's Annual General Meeting (AGM). A total of 1,731 shareholders were present at the meeting held in Basel, representing approximately 62.6% of the issued shares of Novartis.

Laboratory scientists across the globe can now benefit from a software system that helps them manage the entire lab, designed to support process adherence, data integrity and complete regulatory compliance.

A month has gone by since the last earnings report for AbbVie Inc. ABBV . Shares have added about 9.7% in that time frame, outperforming the market.

According to the study published in the Journal of Clinical Endocrinology and Metabolism, the presence of gut flora may be healthy for some people, while it may increase the risk of obesity in others.

On average its rare disease patients – around half of whom are children – have to wait for five years before they receive the correct diagnosis for their condition.

Merck & Co. fell after a federal judge tossed a record $2.54 billion verdict it had won against Gilead Sciences Inc. over a hepatitis treatment.

GPs and general practices are under serious pressure through increasing workloads not least due to more complex cases and the health challenges of an aging population.

In December, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) started a review of the treatment for abnormal bleeding in women with uterine fibroids after four cases of serious liver injury - three resulting in a liver transplant - were reported among users of the drug.

Richard Wolf, answering strong global demand for its high-performance endoscopic technology services, today announced plans to expand in Southeast Asia by opening its 15th subsidiary to be located at the heart of Southeast Asia – Singapore.

Bayer and Loxo Oncology, Inc., , a biopharmaceutical company from Stamford announced the publication in The New England Journal of Medicine (NEJM) of larotrectinib data for the treatment of pediatric and adult patients whose tumors harbor Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusions.

Envigo, a leading provider of nonclinical contract research services and research models, announced the appointment of Lynn Lewis to the position of Senior Vice President, Global Sales.

Contract development and manufacturing organisation (CDMO) Saneca Pharma has announced the appointment of its new CEO, Richard Král.

AbbVie Inc (ABBV.N) said on Thursday its board had approved a $10 billion stock repurchase program, and the drugmaker also increased its quarterly dividend, as it reaped the benefits of U.S. tax law changes.

AstraZeneca and Merck, known as MSD outside the U.S. and Canada, announced that the U.S. FDA has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).

The drug, verubecestat, was being tested in patients who showed only a glimmer of the symptoms that eventually rob them of memories and basic functions. It’s another setback in a long list of experimental treatments that have had little or no effect on the neurodegenerative disease.

UK gene cell therapy designer Oxford BioMedica’s shares jumped  as much as 11.2% to 12.30 pence this morning after announcing a $100 million collaboration and licence agreement with US hemophilia specialist Bioverativ , which last month agreed to be acquired by French pharma major Sanofi in a  $11.6 billion deal.

You do not get severe dengue from the vaccine. Just because you were administered with the vaccine means you’ll get infected. That’s s a little misinformation,” said Dr. Ruby Dizon, Sanofi Pasteur medical director.

Pfizer Inc. (NYSE:PFE) today announced its once-daily oral Janus kinase 1 (JAK1) inhibitor PF-04965842 received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with moderate-to-severe atopic dermatitis (AD).

The world's largest pharmaceutical manufacturing plant is now 98,500 square feet larger.And that expansion -- the most visible part of an ongoing $147 million investment by Pfizer Inc. -- is a very good thing for Portage and Kalamazoo County, local leaders say.

Pimco is the largest bond investor, but it also manages quite a bit in equities. According to S&P Capital IQ, Pimco now oversees $5.1 billion in U.S. equities.

Merck KGaA and Pfizer received a setback on Thursday for their drug Bavencio, which is a late starter in the rapidly evolving field of cancer immunotherapies.

Vetter is one of the winners of the clean manufacturing award CLEAN! 2018. The pharmaceutical service provider was able to convince the independent expert jury of the Fraunhofer Institute for Manufacturing Engineering and Automation (IPA) with its innovative Vetter CleanRoom Technology V-CRT®.

Contract development and manufacturing organisation (CDMO) Recipharm has appointed Bernard Pluta to lead its new global development organisation.

The Pistoia Alliance, a global, not-for-profit alliance that works to lower barriers to innovation in life sciences R&D has today announced the launch of the User Experience (UX) for Life Sciences (LS) Toolkit, to help life science companies improve UX in line with other global industries.

The UXLS toolkit marks the culmination of a collaborative project involving more than 50 UX specialists from 20 different organisations across the world; including several top ten pharmaceutical companies, bioscience, and technology firms. The toolkit contains UX case studies, methods, and metrics – enabling life science companies to design better, more intuitive, more usable digital products, specifically for R&D in the life science and healthcare environment.

These issues and the benefits of UXLS for improving productivity will be discussed further at The Pistoia Alliance’s User Experience for Life Science conference on the 14-15th May 2018 in Boston, USA, featuring keynote speakers from companies including Novartis.

“In today’s world, software is the gateway to unlocking the many zettabytes of data that humans produce. When scientific software is poorly designed, it is frustrating and time-consuming to use, and adds yet another barrier to the acceptance and adoption of new digital technologies, such as automation and Artificial Intelligence. This has the cumulative effect of making drug discovery and development far less efficient and productive,” commented Dr Steve Arlington, President of The Pistoia Alliance.

“As we become more familiar in our personal lives with digital technologies that interact intuitively and respond to our needs, the desire for technology that ‘just works’ in our professional lives is also growing. The potential for good UX design to impact life science R&D is significant – from improving the UX of clinical trials and making it easier for patients to participate, to delivering cutting-edge UX design that supports the ‘laboratory of the future’. UX design should not be considered a remote or niche area, and we hope that our UXLS toolkit enables more companies to realise this potential.”

The UXLS project was formed by The Pistoia Alliance in recognition of the fact that many life science organisations are behind the curve when it comes to UX. Although UX principles are widely recognised and have been applied successfully in other industries, such as retail and financial services, adoption and use in life science is low. Members of The Pistoia Alliance communicated this issue, and the UXLS project began as a result in early 2017.

The project empowers life science professionals to realise the benefits that UX design can deliver through engagement with a wider audience, including stakeholders in senior management. The global UXLS project team worked collaboratively to develop the toolkit which provides a ‘how-to’ that helps businesses adopt UX principles and methods as they develop scientific software.

“At EMBL-EBI, we have a mandate to share data from life science experiments, and put a lot of energy into helping people make the best possible use of it,” says Professor Ewan Birney, Director of the European Bioinformatics Institute. “We experienced a big change when we re-focussed the development of our services and started to adopt a user-centred design process. We benefited from doing user research, prototyping, design and testing to get to the heart of the problem and deliver products and services that are intuitive for researchers. I was initially sceptical, but then I was impressed to see the results across our organisation.”

The UXLS toolkit so far contains six case studies from organisations such as Novartis, EMBL-EBI, and AstraZeneca; 10 published methods, such as interactive prototyping and usability testing; meaningful principles that will assist and explain activities to better a system or process. The toolkit will be beneficial for UX practitioners, bioinformaticians, software developers, and technical and IT managers. The UXLS conference will be hosted by Novartis at the Novartis Institutes for BioMedical Research (NIBR). Pat Keller, Global Head of User Experience at NIBR will deliver a keynote speech at the conference, which will also feature several ‘hands on’ UX workshops.

About The Pistoia Alliance
The Pistoia Alliance is a global, not-for-profit members’ organization made up of life science companies, technology and service providers, publishers, and academic groups working to lower barriers to innovation in life science and healthcare R&D. It was conceived in 2007 and incorporated in 2009 by representatives of AstraZeneca, GSK, Novartis and Pfizer who met at a conference in Pistoia, Italy. Its projects transform R&D through pre-competitive collaboration. It overcomes common R&D obstacles by identifying the root causes, developing standards and best practices, sharing pre-competitive data and knowledge, and implementing technology pilots. There are currently over 80 member companies; members collaborate on projects that generate significant value for the worldwide life sciences R&D community, using the Pistoia Alliance’s proven framework for open innovation.

About the European Bioinformatics Institute (EMBL-EBI)
The European Bioinformatics Institute (EMBL-EBI) is a global leader in the storage, analysis and dissemination of large biological datasets. We help scientists realise the potential of ‘big data’ by enhancing their ability to exploit complex information to make discoveries that benefit humankind. We are at the forefront of computational biology research, with work spanning sequence analysis methods, multi-dimensional statistical analysis and data-driven biological discovery, from plant biology to mammalian development and disease. We are part of EMBL and are located on the Wellcome Genome Campus, one of the world’s largest concentrations of scientific and technical expertise in genomics. Website: www.ebi.ac.uk

 

Aptar Pharma, a leading provider of innovative drug delivery systems, will host a live educational webinar on the benefits of connected drug delivery devices, with a particular focus on improving patient regimen compliance and outlining the benefits to the whole healthcare ecosystem.

Clariant, a world leader in Specialty Chemicals, and its Healthcare Packaging business unit, is introducing a new brand name to encompass all of the products and technology related to equilibrium relative humidity (ERH) stabilization.

Sandoz, a Novartis division and the global leader in biosimilars, announced a global partnership with Asia's premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.

Cmed, an innovative technology-led CRO, will demonstrate the eSource and live data analytics capabilities of encapsia®, a next generation clinical data suite, at Summit for Clinical Operations Executives 2018 this month.

TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced two key new senior leadership appointments: John Hogan hired as senior vice president of engineering and Bob Sturim promoted as Chief Technology Officer.

CluePoints, a leading provider of Risk-Based Monitoring (RBM) and Data Quality Oversight solutions for clinical trials, has been honoured in this year’s Biotechnology Awards with the CluePoints® solution being named the “Best Risk-Based Monitoring Solution”.

CRF Health, a leading global provider of patient-centered eSource technology and service solutions for the life sciences industry, has announced the appointment of former Novartis veteran and eClinical Quality Assurance and Data Integrity Specialist, Tom Haag, as Vice President, Quality Assurance.

Global API developer and manufacturer, Sterling Pharma Solutions, has experienced growth in the Japanese market as a result of its technical capabilities and innovation strategy.

Porex Corporation will showcase advanced solutions for laboratory and medical professionals that speed fluid transfer of diagnostics, improve accuracy and purity in liquid handling, and enhance wound management and improve clinical outcomes.

Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).

A New Year report from CPhI forecasts 2018 will be a transformative year for Japanese pharma as the market evolves towards growth in generics, biosimilars and increased internationalisation.

A new serialisation implementation partner has formed to assist the increasing number of companies needing to meet the data requirements of looming global regulation changes.

Innovative medical technology is an increasingly important driver for delivering efficiencies in the global healthcare system.

TFS is delighted to announce that Dr János Filakovský MD, PhD, MBA has accepted the position of CEO. János brings a wealth of experience to TFS from the Life Science Industry, including over 20 years serving in different leadership roles at Quintiles.

Amgen announced that the U.S. FDA has approved the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma.

Supporting trace element analysis across the environmental, food safety, pharmaceutical and industrial markets, Thermo Fisher Scientific is showcasing its latest inductively coupled plasma mass spectrometry (ICP-MS) and inductively coupled plasma optical emission spectrometry (ICP-OES) solutions and techniques at the 2018 Winter Conference on Plasma Spectrochemistry in Amelia Island, Florida in booth 43-45.

Aptar Pharma, a leading drug delivery systems provider, will once again bea key exhibitor at Pharmapack 2018, Europe's dedicated pharmaceutical packaging and drug delivery event, which takes place on February 7-8 at Paris Expo, Porte de Versailles, France.

Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, is pleased to announce the addition of four highly successful and accomplished biotech executives to the management team.

Juniper Pharma Services , a subsidiary of Juniper Pharmaceuticals, Inc, is proud to announce that its co-founder Martyn Davies has been appointed as a Commander of the Order of the British Empire (CBE) in Her Majesty’s 2018 New Year’s Honours List.

Industry experts from bioLIVE – the new UBM biomanufacturing and bioprocessing event taking place next year in Madrid (October 9-11).

UBM India celebrates the industry with a dazzling array of comprehensive, path-breaking events under the India Pharma Week umbrella.

BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:

Slovakia-based contract development and manufacturing organization (CDMO) Saneca Pharma has strengthened its team with the appointment of a new CDMO sales director as it continues to implement its global growth strategy.

With nearly 30 years’ experience in the industry, having held positions in a number of worldwide CDMO and contract research companies, Markus Saal joins the senior team at Saneca to head up its finished dosage form (FDF) sales and business development activity.

In addition to being a leading global contract development and manufacturing organization, Vetter is also a leader in the area of occupational health management.

Agendia, a world leader in personalized medicine and molecular cancer diagnostics, and University Hospitals Leuven (UZ Leuven) in Belgium have partnered to co-validate Agendia’s new in vitro diagnostic (IVD) MammaPrint® BluePrint® Breast Cancer Risk of Recurrence and Molecular Subtyping Kit.

In concert with its Brazilian partner, the iHealth Group, Clinerion has agreed with Bioserv SMO to add Bioserv’s trial sites to the PRS platform. The Hospital São Vicente de Paulo is the first implementation, bringing another 540 thousand patient lives to Clinerion’s coverage in Brazil.

Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, has established a new agreement with clinical-stage gene therapy company, MeiraGTx.

Worldwide Clinical Trials (www.worldwide.com) has been recognized by Medidata , the leading global provider of cloud-based solutions and data analytics for clinical research, with the first annual Medidata Accelerator Award.

NBE Therapeutics AG, a biopharmaceutical company developing next-generation ADCs carrying highly potent, immune-stimulatory anthracycline toxins, announces the appointment of Dr. Nicole Onetto to its Board of Directors.

UBM India, India's leading B2B exhibition organizer saw the launch of the grand 11th edition of the signature event, CPhI & P-MEC India 2017, one of the world’s leading pharma networking expos.

Essentra, a global leader in healthcare packaging, will showcase its innovative pharmaceutical packaging, labels, serialisation and patient adherence solutions at CPhI India, 27-29th November 2017.

Tartu University Hospital, the only university hospital in Estonia and an e-Health pioneer, has joined the network of hospitals on Clinerion’s PRS platform.

Show more
Show less